



FG Neuro Psychosis

Pharmacogenetics of Psychotic
Disorders

SYNLAB 
SOLUTIONS IN DIAGNOSTICS

www.synlab-sd.com



Why undergoing this examination?

The prevalence of psychotic disorders is 0.85% in the world population. Among these disorders, the most important ones are schizophrenia, bipolar psychosis, and organic psychoses. Treatment depends on the origin of psychotic disorder, as generally, antipsychotic medications, psychological therapy, and various psychosocial supports are used.

Determining factors involved in selecting an antipsychotic in an individual patient include: the primary diagnosis, psychiatric and physical comorbidities, previous treatment effects, patient preferences, treatment availability and different formulations, and above all, the expected efficacy along with drug tolerance and safety.

Despite the correct administration of antipsychotic medications, many patients do not show adequate results or experience adverse effects. The main cause is the presence of variants in the human genome, responsible for modulating the individual response to medications.

What is the exam?

The **FG Neuro Psychosis** pharmacogenetic panel evaluates variants in genes responsible for the main metabolizing enzymes involved in the metabolism of antipsychotic drugs, as well as transport proteins and therapeutic targets. The analysis provides relevant information on the 14 most used drugs, based on the study of genetic variants present in the cytochrome P450 enzymes: **CYP2D6**, **CYP3A4**, **CYP1A2**, and the **CACNG2** gene.

For whom is it indicated?

- Patients undergoing antipsychotic treatment who want to personalize treatment based on their genetic profile;
- Patients for whom antipsychotic treatment does not yield expected results.

Technology

Next-generation sequencing (NGS).

Advantages

SYNLAB GROUP

Detailed report, including the type of metabolism of each enzyme, which drugs may cause toxic effects and adverse reactions, as well as recommendations on doses.

COMPLETE

Laudo detalhado no qual se inclui, além do tipo de metabolismo de cada enzima, quais fármacos podem gerar efeitos tóxicos e reações adversas, assim como recomendações sobre as doses.

Extra Information

DOCUMENTATION - Available on the SYNLAB Direct for clients

- Informed Consent;
- Clinical Questionnaire;
- Medical Request.

PREPARATION

- Fasting is not necessary for the exam.



Delivery Time

22 business days



Sample Type

5 mL of whole blood in EDTA

Additional Information

Studied Drugs		
Aripiprazole*	Haloperidol*	Lithium
Chlorpromazine	Levomepromazine	Quetiapine
Clozapine*	Olanzapine	Risperidone*
Fluphenazine	Perphenazine*	Zuclopenthixol*
Flupentixol*	Pimozide*	

*Drugs for which the FDA (Food and Drug Administration - USA) and/or EMEA (European Medicine Agency) have approved the inclusion of pharmacogenomic information in their labels.